Remicade

GPTKB entity

Statements (59)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:bfsLayer 3
gptkbp:bfsParent gptkb:Johnson_&_Johnson
gptkbp:activities TNF-alpha inhibitor
gptkbp:approves gptkb:1998
gptkb:FDA
gptkbp:brand infliximab
gptkbp:class gptkb:monoclonal_antibody
gptkb:drug
gptkbp:clinical_trial Phase III
Avsola
Inflectra
Renflexis
gptkbp:contraindication heart failure
active infections
hypersensitivity to infliximab
gptkbp:dosage_form solution for infusion
gptkbp:education informed consent required
monitor for signs of infection
gptkbp:formulation lyophilized powder
gptkbp:frequency every 6 to 8 weeks
https://www.w3.org/2000/01/rdf-schema#label Remicade
gptkbp:indication gptkb:Crohn's_disease
gptkb:ulcerative_colitis
gptkb:rheumatoid_arthritis
gptkb:ankylosing_spondylitis
psoriasis
gptkbp:ingredients infliximab
gptkbp:invention gptkb:2018
gptkbp:is_monitored_by liver function tests
complete blood count
tuberculosis screening
gptkbp:is_used_for treatment of autoimmune diseases
gptkbp:manager intravenous
gptkbp:manufacturer gptkb:Johnson_&_Johnson
gptkbp:marketed_as gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
gptkbp:pharmacokinetics dose-dependent clearance
half-life of 8 to 10 days
inhibition of TNF-alpha
gptkbp:population gptkb:Person
adults
gptkbp:price high
gptkbp:provides_information_on recommended for severe cases
used in combination with methotrexate
gptkbp:requires available online
gptkbp:research clinical studies
off-label uses
gptkbp:scholarships gptkb:stock_market_index
gptkbp:side_effect fatigue
headache
nausea
infections
autoimmune disorders
infusion reactions
serious infections
malignancies
gptkbp:storage refrigerated